AXON Connected
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $2.1m | Seed | |
$20.0k | Grant | ||
Total Funding | €1.9m |
Related Content
Recent News about AXON Connected
EditAxon Connected operates in the biotechnology and telecommunications sectors, focusing on developing innovative solutions to address market needs. The company serves a diverse range of clients, including universities, non-profits, federal labs, and industry partners. Axon Connected's business model revolves around identifying market demands and creating products and services that offer tangible improvements in technology, environment, and life sciences. The company generates revenue through the commercialization of its products, such as AxImmune, an immune system enhancement drug aimed at improving outcomes for cancer patients on immune checkpoint inhibitors like Keytruda and Opdivo. Additionally, Axon Optics develops advanced optical instrumentation for the telecommunications industry. By leveraging strategic planning, team building, and investment, Axon Connected aims to scale up its operations and achieve profitability.
Keywords: biotechnology, telecommunications, immune enhancement, cancer treatment, optical instrumentation, market-driven solutions, strategic planning, commercialization, innovation, profitability.